Skip to main content
. 2017 Mar 17;8(24):38351–38366. doi: 10.18632/oncotarget.16323

Figure 9. VPA treatment in a subcutaneous human colon tumor xenograft.

Figure 9

(A) Tumor growth was measured daily before and throughout the intraperitoneal administration of VPA (500 mg/kg) for 30 days. Data represent the relative tumor volume plotted as a function of time. Five mice, each bearing two individual tumors, were included in each group. Mann-Whitney parametric test, **p < 0.02. (B) Immunohistochemical CXCL12 expression in human colon cancer xenografts treated with 500 mg/kg VPA for 30 days and control (untreated) xenografts. (C) Enlargement of a part of the pictures shown in B. The results represent five mice per group.